$14.8 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 116 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SMH | New | VANECK VECTORS ETF TRUSTput | $354,232,000 | – | 2,505,000 | +100.0% | 2.39% | – |
| MDCO | New | MEDICINES CO | $281,576,000 | – | 3,315,000 | +100.0% | 1.90% | – |
| CRM | New | SALESFORCE COM INC | $280,534,000 | – | 1,724,880 | +100.0% | 1.89% | – |
| TMO | New | THERMO FISHER SCIENTIFIC INC | $277,166,000 | – | 853,160 | +100.0% | 1.87% | – |
| BRMK | New | BROADMARK RLTY CAP INC | $91,476,000 | – | 7,174,613 | +100.0% | 0.62% | – |
| BMYRT | New | BRISTOL MYERS SQUIBB COright 99/99/9999 | $91,429,000 | – | 30,374,950 | +100.0% | 0.62% | – |
| AXE | New | ANIXTER INTL INC | $84,538,000 | – | 917,893 | +100.0% | 0.57% | – |
| QGEN | New | QIAGEN NV | $72,805,000 | – | 2,154,000 | +100.0% | 0.49% | – |
| BOLD | New | AUDENTES THERAPEUTICS INC | $71,210,000 | – | 1,190,000 | +100.0% | 0.48% | – |
| AGIO | New | AGIOS PHARMACEUTICALS INC | $59,688,000 | – | 1,250,000 | +100.0% | 0.40% | – |
| RARX | New | RA PHARMACEUTICALS INC | $55,758,000 | – | 1,188,100 | +100.0% | 0.38% | – |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $54,258,000 | – | 2,750,000 | +100.0% | 0.37% | – |
| SRPT | New | SAREPTA THERAPEUTICS INCcall | $51,616,000 | – | 400,000 | +100.0% | 0.35% | – |
| ARQL | New | ARQULE INC | $50,299,000 | – | 2,520,000 | +100.0% | 0.34% | – |
| KRTX | New | KARUNA THERAPEUTICS INC | $45,204,000 | – | 600,000 | +100.0% | 0.30% | – |
| New | KARYOPHARM THERAPEUTICS INCnote 3.000%10/1 | $34,430,000 | – | 24,000,000 | +100.0% | 0.23% | – | |
| TIF | New | TIFFANY & CO NEW | $30,071,000 | – | 225,000 | +100.0% | 0.20% | – |
| INST | New | INSTRUCTURE INC | $29,890,000 | – | 620,000 | +100.0% | 0.20% | – |
| New | INTERCEPT PHARMACEUTICALS INnote 2.000% 5/1 | $23,148,000 | – | 17,500,000 | +100.0% | 0.16% | – | |
| PRNB | New | PRINCIPIA BIOPHARMA INC | $21,912,000 | – | 400,000 | +100.0% | 0.15% | – |
| AMRN | New | AMARIN CORP PLCcall | $21,440,000 | – | 1,000,000 | +100.0% | 0.14% | – |
| WMGI | New | WRIGHT MED GROUP N V | $21,031,000 | – | 690,000 | +100.0% | 0.14% | – |
| HRTX | New | HERON THERAPEUTICS INC | $20,563,000 | – | 875,000 | +100.0% | 0.14% | – |
| NLOK | New | NORTONLIFELOCK INC | $18,374,000 | – | 720,000 | +100.0% | 0.12% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $15,420,000 | – | 3,000,000 | +100.0% | 0.10% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $15,310,000 | – | 500,000 | +100.0% | 0.10% | – |
| LVGO | New | LIVONGO HEALTH INC | $15,036,000 | – | 600,000 | +100.0% | 0.10% | – |
| LOGM | New | LOGMEIN INC | $11,167,000 | – | 130,241 | +100.0% | 0.08% | – |
| OPTN | New | OPTINOSE INC | $8,298,000 | – | 900,000 | +100.0% | 0.06% | – |
| RCKT | New | ROCKET PHARMACEUTICALS INC | $8,059,000 | – | 354,082 | +100.0% | 0.05% | – |
| ABEO | New | ABEONA THERAPEUTICS INC | $6,540,000 | – | 2,000,000 | +100.0% | 0.04% | – |
| OYST | New | OYSTER POINT PHARMA INC | $5,641,000 | – | 230,800 | +100.0% | 0.04% | – |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $5,513,000 | – | 334,706 | +100.0% | 0.04% | – |
| XRX | New | XEROX HOLDINGS CORP | $4,793,000 | – | 130,000 | +100.0% | 0.03% | – |
| OPK | New | OPKO HEALTH INC | $3,675,000 | – | 2,500,000 | +100.0% | 0.02% | – |
| BRMKWS | New | BROADMARK RLTY CAP INC*w exp 11/15/202 | $2,726,000 | – | 7,174,613 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-05-15 |
| 13F-HR/A | 2024-05-15 |
| 13F-HR | 2024-05-15 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.